Selenium, Ltd. Receives National Institutes of Health (NIH) Research Grant from the National Institute on Deafness and Other Communication Disorders

LUBBOCK, Texas & AUSTIN, Texas--(BUSINESS WIRE)--Selenium, Ltd., a biopharmaceutical company focused on unique solutions to meet antimicrobial coating and therapeutic needs, has been awarded a research grant from the National Institute on Deafness and Other Communication Disorders, one of the National Institutes of Health. With the $155,387 NIH grant the company will apply its proprietary antimicrobial technology to researching the inhibition of biofilms on tympanostomy tubes. Selenium’s SeLECTTM technology addresses the need for a safer, more effective and less costly antimicrobial coating technology that can reduce the risk of bacterial infection.